X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Merus will use the proceeds to advance the clinical development of its candidates, including MCLA-158 (petosemtamab), a Biclonics® low-fucose human full-length IgG1 antibody targeting the EGFR.
Lead Product(s): Petosemtamab,Pembrolizumab
Therapeutic Area: Oncology Product Name: MCLA-158
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $400.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 29, 2024
Details:
The net proceeds will be used to advance the clinical development of MCLA-158 (petosemtamab), an EGFR inhibitor. It is being evaluated for the treatment of head and neck and colorectal cancer.
Lead Product(s): Petosemtamab,Pembrolizumab
Therapeutic Area: Oncology Product Name: MCLA-158
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 28, 2024
Details:
MCLA-158 (petosemtamab) is a IgG1 bispecific antibody targeting EGFR and LGR5. It is being investigated as a treatment for recurrent or metastatic HNSCC in combination with pembrolizumab.
Lead Product(s): Petosemtamab,Pembrolizumab
Therapeutic Area: Oncology Product Name: MCLA-158
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2024
Details:
MCLA-158 (petosemtamab) full-length IgG1 bispecific antibody targeting EGFR and LGR5. It is being evaluated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Lead Product(s): Petosemtamab,Pembrolizumab
Therapeutic Area: Oncology Product Name: MCLA-158
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2024
Details:
Zeno (zenocutuzumab) is a bispecific antibody currently under evaluation in patients for treating NRG1+ non-small cell lung and NRG1+ pancreatic cancer.
Lead Product(s): Zenocutuzumab
Therapeutic Area: Oncology Product Name: Zeno
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2024
Details:
The collaboration aims to use Merus’ proprietary Triclonics® platform along with Gilead’s oncology expertise to research and develop multiple, separate preclinical research programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $1,581.0 million Upfront Cash: $56.0 million
Deal Type: Collaboration March 06, 2024
Details:
Merus currently intends to use the net proceeds to advance the clinical development of its product candidates including, MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA).
Lead Product(s): Petosemtamab
Therapeutic Area: Oncology Product Name: MCLA-158
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 09, 2023
Details:
MCLA-128 (zenocutuzumab) is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics® that utilizes the Merus Dock & Block® mechanism to inhibit the neuregulin/HER3 tumor-signaling pathway in solid tumors with NRG1 fusions (NRG1+ cancer).
Lead Product(s): Zenocutuzumab
Therapeutic Area: Oncology Product Name: MCLA-128
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
MCLA-128 (zenocutuzumab) is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced Biclonics® that utilizes the Merus Dock & Block® mechanism to inhibit the neuregulin/HER3 tumor-signaling pathway in solid tumors with NRG1 fusions (NRG1+ cancer).
Lead Product(s): Zenocutuzumab
Therapeutic Area: Oncology Product Name: MCLA-128
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2023
Details:
Petosemtamab, or MCLA-158, is a human IgG1 Biclonics® designed to bind to cancer cells expressing EGFR and leucine-rich repeat-containing G protein-coupled receptor 5. It is being investigated for head and neck squamous cell carcinoma.
Lead Product(s): Petosemtamab
Therapeutic Area: Oncology Product Name: MCLA-158
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
